IL295014B1 - A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma - Google Patents
A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipomaInfo
- Publication number
- IL295014B1 IL295014B1 IL295014A IL29501422A IL295014B1 IL 295014 B1 IL295014 B1 IL 295014B1 IL 295014 A IL295014 A IL 295014A IL 29501422 A IL29501422 A IL 29501422A IL 295014 B1 IL295014 B1 IL 295014B1
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- angiolipoma
- acid
- weight
- dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Preparations (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966577P | 2020-01-28 | 2020-01-28 | |
| PCT/IB2021/000035 WO2021152390A1 (en) | 2020-01-28 | 2021-01-27 | Compositions for the treatment of angiolipoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL295014A IL295014A (en) | 2022-09-01 |
| IL295014B1 true IL295014B1 (en) | 2026-05-01 |
Family
ID=77078612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295014A IL295014B1 (en) | 2020-01-28 | 2021-01-27 | A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230089484A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4096653A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7850665B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN115335047B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021213469B2 (cg-RX-API-DMAC10.html) |
| IL (1) | IL295014B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021152390A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016203468A1 (en) | 2015-06-15 | 2016-12-22 | Raziel Therapeutics Ltd. | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof |
| EP4031130A4 (en) * | 2019-09-15 | 2023-10-11 | Raziel Therapeutics Ltd. | COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS |
| US20240335424A1 (en) * | 2021-07-28 | 2024-10-10 | Raziel Therapeutics Ltd. | Compositions and methods for treating lipoma pain |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013072915A1 (en) * | 2011-11-15 | 2013-05-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Tricyclic compounds, compositions comprising them and uses thereof |
| WO2015061280A1 (en) * | 2013-10-21 | 2015-04-30 | Alevere Medical Corporation | Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016020919A1 (en) * | 2014-08-07 | 2016-02-11 | Raziel Therapeutics Ltd. | Compositions comprising tricyclic compounds, and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011058139A1 (en) * | 2009-11-12 | 2011-05-19 | Selvita Sp. Z O. O. | A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| RU2020111934A (ru) * | 2013-10-08 | 2020-04-29 | Промедиор, Инк. | Способы лечения фиброзного рака |
| WO2016203468A1 (en) * | 2015-06-15 | 2016-12-22 | Raziel Therapeutics Ltd. | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof |
-
2021
- 2021-01-27 AU AU2021213469A patent/AU2021213469B2/en active Active
- 2021-01-27 EP EP21748312.2A patent/EP4096653A4/en active Pending
- 2021-01-27 US US17/795,204 patent/US20230089484A1/en active Pending
- 2021-01-27 JP JP2022542777A patent/JP7850665B2/ja active Active
- 2021-01-27 CN CN202180025551.1A patent/CN115335047B/zh active Active
- 2021-01-27 WO PCT/IB2021/000035 patent/WO2021152390A1/en not_active Ceased
- 2021-01-27 IL IL295014A patent/IL295014B1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013072915A1 (en) * | 2011-11-15 | 2013-05-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Tricyclic compounds, compositions comprising them and uses thereof |
| WO2015061280A1 (en) * | 2013-10-21 | 2015-04-30 | Alevere Medical Corporation | Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016020919A1 (en) * | 2014-08-07 | 2016-02-11 | Raziel Therapeutics Ltd. | Compositions comprising tricyclic compounds, and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| CLINICAL TRIAL NCT04229030 (PHASE 2B)., RZL-012 FOR DERCUM'S DISEASE LIPOMAS, 14 January 2020 (2020-01-14) * |
| SHIN YS, ET AL., SONOGRAPHIC DIFFERENTIATION BETWEEN ANGIOLIPOMAS AND SUPERFICIAL LIPOMAS, 30 November 2016 (2016-11-30) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115335047B (zh) | 2025-09-19 |
| CN115335047A (zh) | 2022-11-11 |
| JP7850665B2 (ja) | 2026-04-23 |
| AU2021213469B2 (en) | 2026-06-04 |
| IL295014A (en) | 2022-09-01 |
| EP4096653A1 (en) | 2022-12-07 |
| AU2021213469A1 (en) | 2022-08-25 |
| WO2021152390A1 (en) | 2021-08-05 |
| EP4096653A4 (en) | 2024-02-28 |
| US20230089484A1 (en) | 2023-03-23 |
| JP2023510865A (ja) | 2023-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102375262B9 (en) | GLP-1 Pharmaceutical composition comprising sustained release-microsphere comprising GLP-1 Analogue or pharmaceutically acceptable salt thereof | |
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| FI4054719T3 (fi) | Ras-estäjiä | |
| EP4424328A3 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| PH12021551302A1 (en) | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | |
| PH12022550448A1 (en) | Niclosamide delayed-release composition and antiviral use thereof | |
| PL3829628T3 (pl) | Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5 | |
| SA519401614B1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| MX2025005474A (es) | Farmaco farmaceutico que contiene derivado de heterocicliden acetamida | |
| AR038618A1 (es) | Forma poliformica cristalina de clorhidratos de irinotecan | |
| PL4277628T3 (pl) | Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego | |
| CA3264923A1 (en) | COMPOSITION INTENDED FOR USE IN THE TREATMENT OF FABRY'S DISEASE | |
| MX2021005944A (es) | Inhibidores de rip1. | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| PH12019502767A1 (en) | Oral pharmaceutical formulations of remogliflozin | |
| KR102467285B9 (ko) | 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물 | |
| MX2016009226A (es) | Combinaciones farmaceuticas. | |
| NZ593282A (en) | Ethanamine compounds and their use for treating depression | |
| MX2023013301A (es) | Una pluralidad de particulas tasquinimod y su uso. | |
| IL306116A (en) | New compounds with inhibitory activity against glucosylceramide synthase or an acceptable pharmaceutical salt thereof, processes for their preparation and pharmaceutical preparations containing them | |
| ZA202200331B (en) | Naltrexone formulation | |
| HRP20230693T1 (hr) | Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti |